This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy.
Wondering if you qualify as a candidate for this trial? Visit the "View Trial" button below and print the the trial's details to discuss with your Cancer Care Northwest physician.
For More Information
If you are interested in this clinical trial, please email the Cancer Care Northwest Research Department at firstname.lastname@example.org for more information. Be sure to include: